The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma
Tycel Phillips, MD, City of Hope, Duarte, CA, comments on a retrospective analysis of treatment patterns and patient outcomes across lines of therapy in relapsed/refractory (R/R) follicular lymphoma (FL). The study investigated how various patient variables impact outcomes and observed the patterns and trends in the treatment approaches used by physicians. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, AstraZeneca, Bayer, Beigene, BMS, Cardinal Health, Epizyme, Incyte, Karyopharm, Pharmacyclics, Seattle Genetics
Research Funding: Abbvie, Bayer
